Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)

2024-11-1020220923-753410.1016/j.annonc.2022.07.1876http://dx.doi.org/10.1016/j.annonc.2022.07.1876https://hdl.handle.net/20.500.14288/15853N/AOncologyPhase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)Meeting Abstract1569-8041866211601462Q16088